Gastric Neuroendocrine Tumor G1
1 clinical trials · Condition
◉ Watch Gastric Neuroendocrine Tumor G1
| Record | Firm | Date |
|---|---|---|
| Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor (NCT00569127) | National Cancer Institute (NCI) | 2007-12-01 |
Track Gastric Neuroendocrine Tumor G1 automatically
Every clearance here is in the API, with alerts when new ones post.